WO2023061415 - THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF

National phase entry:
Publication Number WO/2023/061415
Publication Date 20.04.2023
International Application No. PCT/CN2022/124933
International Filing Date 12.10.2022
Title **
[English] THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF
[French] DÉRIVÉS DE THIADIAZOLYLE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
Applicants **
DANATLAS PHARMACEUTICALS CO., LTD.
Inventors
ZHANG, Yao
LI, Hongmei
Priority Data
PCT/CN2021/124155   15.10.2021   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3115
EPO Filing, Examination, Granting30395
Japan Filing, Examination, Granting3263
South Korea Filing, Examination, Granting4508
USA Filing, Examination, Granting16940
MasterCard Visa
Total: 58,221

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] The disclosure relates to thiadiazolyl derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.[French] L'invention concerne des dérivés de thiadiazolyle tels que représentés dans la formule (I), des compositions pharmaceutiques les comprenant, un procédé pour leur préparation, et leur utilisation en tant qu'agents thérapeutiques.